Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPO study of reduced enzyme replacement therapy frequency in late-onset Pompe disease
NL-OMON60370Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Erasmus MC. Started Jun 2025; status: recruiting.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON60370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60370.